Abstract
The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT/NE reuptake inhibitors duloxetine and venlafaxine was compared. Duloxetine inhibited binding to the human NE and 5-HT transporters with Ki values of 7.5 and 0.8 nM, respectively, and with a Ki ratio of 9. Venlafaxine inhibited binding to the human NE and 5-HT transporters with Ki values of 2480 and 82 nM, respectively, and with a Ki ratio of 30. Duloxetine inhibited ex vivo binding to rat 5-HT transporters and NE transporters with ED50 values of 0.03 and 0.7 mg/kg, respectively, whereas venlafaxine had ED50 values of 2 and 54 mg/kg, respectively. The depletion of rat brain 5-HT by p-chloramphetamine and depletion of rat hypothalamic NE by 6-hydroxydopamine was blocked by duloxetine with ED50 values of 2.3 and 12 mg/kg, respectively. Venlafaxine had ED50 values of 5.9 and 94 mg/kg for blocking p-chloramphetamine– and 6-hydroxydopamine–induced monoamine depletion, respectively. Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA . (1993): Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90: 408–412
Anderson IM . (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disorders 58: 19–36
Artigas F . (1995): Selective serotonin/noradrenaline reuptake inhibitors (SNRIs) Pharmacology and therapeutic potential in the treatment of depressive disorders. CNS Drugs 4: 79–89
Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL . (1993): Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem 268: 23422–23426
Béïque JC, Lavoie N, de Montigny C, Debonnel G . (1998): Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 349: 129–132
Béïque JC, de Montigny C, Blier P, Debonnel G . (1999): Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32: 198–211
Berk M, du Plessis A, Birkett M, Richardt D, on behalf of the Lilly Duloxetine study group. (1997): An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenergic reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Int Clin Psychopharmacol 12: 137–140
Blier P, de Montigny C . (1994): Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220–226
Boess FG, Monsma FJ Jr, Carolo C, Meyer V, Rudler A, Zwingelstein C, Sleight AJ . (1997): Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacol 36: 713–720
Bolden-Watson C, Richelson E . (1993): Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52: 1023–1029
Cheng YC, Prusoff WH . (1973): Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes a 50 percent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3090–3108
Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR . (1990): Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47: 411–418
Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, Charney DS . (1993): Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 29: 389–396
Engleman EA, Perry KW, Mayle DA, Wong DT . (1995): Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacol 12: 287–295
Engleman EA, Robertson DW, Thompson DC, Perry KW, Wong DT . (1996): Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J Neurochem 66: 599–603
Fuller RW, Hemrick-Luecke SK, Snoddy HD . (1994): Effects of duloxetine, an antidepressant drug candidate, on concentrations on monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther 269: 132–136
Fuller RW, Perry KW . (1989): Effects of buspirone and its metabolite, 1-(2-pyrimidinyl)piperazine, on brain monoamines and their metabolites in rats. J Pharmacol Exp Ther 248: 50–56
Fuller RW, Warren BJ, Malloy BB . (1970): Selective inhibition of monoamine oxidase in rat brain mitochondria. Biochem Pharmacol 19: 2934–2936
Gobert A, Rivet J-M, Cistarelli L, Melon C, Millan MJ . (1997): Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 69: 2616–2619
Kasamo K, Blier P, de Montigny C . (1996): Blockade of serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 277: 278–286
Katoh A, Eigyo M, Ishibashi C, Naitoh Y, Takeuchi M, Ibii N, Ikeda M, Matsushita A . (1995): Behavioral and electroencephalographic properties of duloxetine (LY248686), a re-uptake inhibitor of noradrenaline and serotonin, in mice and rats. J Pharmacol Exp Ther 272: 1067–1075
Kihara T, Ikeda M . (1995): Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 272: 177–183
Mendels J, Johnston R, Mattes J, Riesenberg R . (1993): Efficacy and safety of b.i.d. doses of venlafaxine in a dose response study. Psychopharmacol Bull 29: 169–174
Millan MJ, Brocco M, Veiga S, Cistarelli L, Melon C, Gobert A . (1998): WAY 100,635 enhances both the “antidepressant” actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex. Eur J Pharmacol 341: 165–167
Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB . (1986): Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35: 4493–4497
Nelson JC . (1998): Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry 59(suppl 5): 65–68
Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI . (1991): A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of depression. Arch Gen Psychiatry 48: 303–307
Reneric J-P, Lucki I . (1998): Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacol 136: 190–197
Roose SP, Glassman AH, Walsh BT, Woodring S . (1986): Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 143: 345–348
Schildkraut JJ . (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122: 509–522
Schweizer E, Feighner J, Mandos LA, Rickels K . (1994): Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55: 104–108
Seth R, Jennings AL, Bindman J, Phillips J, Bergman K . (1992): Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161: 562–565
Tatsumi M, Groshan K, Blakely RD, Richelson E . (1997): Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249–258
Thase ME, Rush AJ . (1995): Treatment-resistant depression. In Bloom FE, Kupfler DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 1081–1097
Troy SM, Parker VD, Hicks DR, Boudino D, Chiang ST . (1996): Pharmacokinetic interaction between multiple-dose venlafaxine and single dose lithium. J Clin Pharmacol 36: 175–181
Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL . (1996): Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther 276: 720–727
Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K . (1989): Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 50: 447–449
Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR . (1992): Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci USA 89: 3630–3634
Wong DT . (1998): Duloxetine (LY248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Exp Opin Invest Drugs 7: 1–9
Wong DT, Bymaster FP, Engleman EE . (1995): Prozac (fluoxetine, LILLY 110140), the first selective uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57: 411–441
Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW . (1993): LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacol 8: 23–33
Zgombick JM, Weinshank RL, Macchi M, Schechter LE, Branchek TA, Hartig PR . (1991): Expression and pharmacological characterization of a canine 5- hydroxytryptamine1D receptor subtype. Mol Pharmacol 40: 1036–1042
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bymaster, F., Dreshfield-Ahmad, L., Threlkeld, P. et al. Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors. Neuropsychopharmacol 25, 871–880 (2001). https://doi.org/10.1016/S0893-133X(01)00298-6
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00298-6
Keywords
This article is cited by
-
Understanding the differential impacts of two antidepressants on locomotion of freshwater snails (Lymnaea stagnalis)
Environmental Science and Pollution Research (2024)
-
Daily intake of 30 mg duloxetine is effective in decreasing premature ejaculation severity: a prospective randomized placebo-controlled cross over clinical trial
Basic and Clinical Andrology (2023)
-
A randomized, double-blinded, placebo-controlled clinical trial of duloxetine hydrochloride enteric-coated tablets in the treatment of refractory chronic cough
BMC Pulmonary Medicine (2023)
-
Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study
Translational Psychiatry (2022)
-
Glycerosomal thermosensitive in situ gel of duloxetine HCl as a novel nanoplatform for rectal delivery: in vitro optimization and in vivo appraisal
Drug Delivery and Translational Research (2022)
